Congress tradeHeld by the filer's joint per the disclosure. Disclosed 824 days after the transaction; reported as an official range, not an exact amount.
Loading…
Traded Jul 2, 2026 · Filed Jul 7, 2026
Vertex Pharmaceuticals's Chief Commercial Officer sold $800K of Vertex Pharmaceuticals shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$799,779
Shares × reported transaction price
59 days after results of May 4, 2026, 32 days before results of Aug 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $528.04 on Jul 2, 2026, at its 52-week high, after a 22% rise over the previous 30 trading days
52-week range $366.54 (Aug 8, 2025) to $528.04 (Jul 2, 2026), 100% of the way up, from 251 adjusted closes. 30 trading days earlier: $434.31 on May 19, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -4.3% | +1.3% | -5.5% |
| 30 days | -0.5% | +3.7% | -4.2% |
Past results only. Not a forecast.
Held by the filer's joint per the disclosure. Disclosed 824 days after the transaction; reported as an official range, not an exact amount.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.